Purdue Pharma and the Sackler families agreed Thursday to increase their financial contribution to $7.4 billion to resolve mass opioid litigation. A new report from the Centers for Disease Control ...

Preparation of a dose of Buprenorphine, an opioid that can be administered to people with opioid-use disorder to blunt cravings for other drugs like fentanyl and reduce the risk of overdose.Credit ...

The three most commonly used opioids were hydrocodone, tramadol, and oxycodone, which are the focus of the presented results unless otherwise specified. Table 1 summarizes characteristics of persons ...

The Aversa™ Fentanyl patch is designed to incorporate Nutriband's proprietary abuse-deterrent technology, which uses taste aversion to discourage misuse and accidental exposure of opioid and ...

Health Union launches Opioid-Use-Disorder.com—offering support ... advertisers can drive awareness, engagement, and conversion results by leveraging the power of Health Union's condition ...

Please provide your email address to receive an email when new articles are posted on . An opioid-free protocol yielded noninferior pain scores vs. an opioid-containing protocol at 24 hours after ...

Vertex Pharmaceuticals (VRTX) stock rose on Friday after the Food and Drug Administration (FDA) approved its new painkiller, the first of its kind approved by regulators. Journavx, or suzetrigine ...

A study showed that changes in the functioning of opioid neurotransmitters in the brain may underlie anorexia. A study conducted at Turku PET Centre in Finland showed that changes in the ...

Endo's slide into bankruptcy follows in the footsteps of Purdue Pharma – which filed in 2019 but is still negotiating opioid settlement and corporate restructuring terms – as well as ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

Vertex Pharmaceuticals (VRTX) stock is rising following Food and Drug Administration (FDA) approval of Journavx, a non-opioid pain medication designed to treat moderate to severe acute pain.